Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Biocept Inc (BIOC)

Biocept Inc (BIOC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Biocept Reports 2022 Financial Results Business Wire - Mon Apr 17, 2023

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update....

BIOC : 0.4349 (-13.05%)
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases Business Wire - Fri Mar 24, 2023

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary...

BIOC : 0.4349 (-13.05%)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Wed Mar 1, 2023

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares...

BIOC : 0.4349 (-13.05%)
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan Business Wire - Fri Jan 6, 2023

Biocept, Inc. (NasdaqCM: BIOC ) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of...

BIOC : 0.4349 (-13.05%)
Biocept Reports Third Quarter 2022 Financial Results Business Wire - Mon Nov 21, 2022

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a...

BIOC : 0.4349 (-13.05%)
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors Business Wire - Fri Nov 18, 2022

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately,...

BIOC : 0.4349 (-13.05%)
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System Business Wire - Wed Nov 16, 2022

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic...

BIOC : 0.4349 (-13.05%)
Biocept Reports Second Quarter 2022 Financial Results Business Wire - Thu Nov 10, 2022

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business...

BIOC : 0.4349 (-13.05%)
Biocept to Present at the LD Micro Main Event XV Business Wire - Wed Oct 19, 2022

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at...

BIOC : 0.4349 (-13.05%)
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System Business Wire - Mon Oct 17, 2022

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patients with metastatic melanoma....

BIOC : 0.4349 (-13.05%)

Barchart Exclusives

1 Growth Stock to Buy Now as the Fed Begins Its Rate-Cut Cycle Barchart - 3 minutes ago
The Fed has kicked off its rate-cut cycle with a 50-basis point cut. SoFi looks like a good stock to buy, as the Fed's rate cuts could revive sagging growth in the U.S. economy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot